PPCB vs PRQR

Propanc Biopharma, Inc. vs ProQR Therapeutics N.V. — Valuation Comparison 2026

PPCB

Biotechnology
Propanc Biopharma, Inc.
Quality
3.7
out of 10
Value Trap
36
LOW
Price
$1.70
Last close
Models
6/13
Active
VS

PRQR

Biotechnology
ProQR Therapeutics N.V.
Quality
5.0
out of 10
Value Trap
18
SAFE
Price
$1.57
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType PPCB Fair ValuePPCB Upside PRQR Fair ValuePRQR Upside
Bayesian DCF Intrinsic $0.50 -70.8% $1.07 -32.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $6.64 +290.6% $0.78 -50.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PPCB vs PRQR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PPCB vs PRQR — Which Stock Is More Undervalued?

PRQR scores higher with a 5.0/10 quality rating vs PPCB's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Propanc Biopharma, Inc. (PPCB) and ProQR Therapeutics N.V. (PRQR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PPCB currently trades at $1.70 with a QOC of 3.7/10, while PRQR trades at $1.57 with a QOC of 5.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).